M

Mineralys Therapeutics

Clinical-stage biopharma targeting aldosterone synthesis

Senior Director - Analytical Sciences

Bioprocess & BiomanufacturingConfirmed live in the last 24 hours
Full-timeRemote in USA

About the Job

Requirements

  • A Ph.D. in Analytical Chemistry, Chemistry, Pharmaceutical Sciences, or a related scientific discipline; an M.S. with substantial directly relevant experience may be considered.
  • Typically 15 or more years of relevant pharmaceutical or biotechnology industry experience, including progressively responsible leadership in analytical development or analytical sciences.
  • Demonstrated experience supporting small molecule products from development through regulatory submission, approval, launch, and commercial lifecycle management.
  • Deep expertise in analytical method development, validation, transfer, stability, specifications, and impurity control for drug substance and drug product.
  • Strong working knowledge of current Good Manufacturing Practice (cGMP) requirements, International Council for Harmonisation (ICH) guidelines, compendial expectations, data integrity principles, and global Chemistry, Manufacturing, and Controls (CMC) regulatory requirements.
  • Proven ability to lead external analytical partners and manage budgets, timelines, and technical risks across multiple programs.
  • Excellent written, verbal, and executive-level communication skills.

Responsibilities

  • Set and lead the analytical direction across the portfolio, ensuring approaches are risk-based, phase-appropriate, and fit for purpose.
  • Serve as the company subject matter expert for analytical chemistry and pharmaceutical analysis.
  • Develop and execute integrated analytical strategies for drug substance, drug product, raw materials, impurities, and reference standards.
  • Own method development, qualification, validation, transfer, verification, and lifecycle management for drug substance and drug product.
  • Establish specifications, impurity control, characterization, reference standards, and stability programs.
  • Provide technical leadership for out-of-specification and out-of-trend investigations, deviations, corrective and preventive actions, and complex analytical troubleshooting.
  • Lead the external analytical network, including contract development and manufacturing organizations, contract research organizations, and contract testing laboratories, covering selection, governance, and review of technical deliverables.
  • Author, review, and approve analytical content for global regulatory submissions and support Health Authority questions, audits, and inspections.
  • Ensure external partners operate in accordance with cGMP requirements, quality agreements, and company standards.
  • Drive analytical readiness for process validation, launch, continued process verification, and post-approval changes.
  • Partner cross-functionally with Drug Substance, Drug Product, Quality, Regulatory, Supply Chain, and Program Management to deliver integrated CMC plans.
  • Manage budgets, timelines, resources, and technical risk across programs; build and mentor the team as the organization grows.
  • Travel up to 10%, frequently outside the local area and overnight.

Desired Qualifications

  • Experience in a virtual, externally networked, or substantially outsourced pharmaceutical operating model.
  • Experience with oral solid dosage forms, late-stage development, process validation, and commercial launch readiness.
  • Experience building an Analytical Sciences function and establishing scalable governance and operating processes.

About the Company

Mineralys Therapeutics

Clinical-stage biopharma targeting aldosterone synthesis

Mineralys Therapeutics develops targeted treatments for diseases driven by dysregulated aldosterone, aiming to control blood pressure and prevent organ damage, led by lorundrostat. Lorundrostat is an oral aldosterone synthase inhibitor that blocks the CYP11B2 enzyme to lower aldosterone production, designed to reduce blood pressure with minimal cortisol disruption due to high selectivity. Compared with older non-selective MRAs, it lowers side effects by focusing on aldosterone synthesis rather than receptor blockade. The company's goal is to advance lorundrostat through late-stage trials toward regulatory approval and commercialization, while exploring expanded uses in CKD and OSA for a potential multi-hundred-billion market.

Company size
201-500
Company stage
IPO
Headquarters
Radnor Township, Pennsylvania
Founded
2020

Recently Posted Jobs

Explore more opportunities at Mineralys Therapeutics

See more jobs